Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
116 hedge funds and large institutions have $175M invested in Insys Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 22 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 24
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
2% less funds holding
Funds holding: 118 → 116 (-2)
29% less capital invested
Capital invested by funds: $246M → $175M (-$71.4M)
46% less call options, than puts
Call options by funds: $2.36M | Put options by funds: $4.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$4.12M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$2.73M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.81M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.16M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHAM
Folger Hill Asset Management
New York
|
-$3.96M |
| 2 |
Credit Agricole
Montrouge Cedex,
France
|
-$2.31M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.14M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$1.11M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$892K |
INSY Hedge Fund Activity: Q3 2017 in Review
116 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2017, worth a combined $175M — down 29% from $246M a quarter earlier.
Fund positioning in INSY was balanced in Q3 2017: 22 funds opened new positions, 22 closed out, 37 added to existing stakes and 24 trimmed.
The largest buyer was Mirae Asset Global Investments, adding an estimated $4.12M. The largest seller was Folger Hill Asset Management, cutting an estimated $3.96M.
- 116 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2017, down from 118 in Q2 2017.
- Funds reported $175M of Insys Therapeutics, Inc. stock for Q3 2017, down 29% quarter-over-quarter.
- 22 funds opened new Insys Therapeutics, Inc. positions in Q3 2017 and 22 closed out, a net change of 0 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2017 was Mirae Asset Global Investments, an estimated $4.12M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2017 was Folger Hill Asset Management, an estimated $3.96M sold.
Based on aggregated 13F filings for Q3 2017.